297 related articles for article (PubMed ID: 11747343)
1. Demonstration of mixed properties of RU486 in progesterone receptor (PR)-transfected MDA-MB-231 cells: a model for studying the functions of progesterone analogues.
Lin VC; Aw SE; Ng EH; Ng EH; Tan MG
Br J Cancer; 2001 Dec; 85(12):1978-86. PubMed ID: 11747343
[TBL] [Abstract][Full Text] [Related]
2. Progestins inhibit the growth of MDA-MB-231 cells transfected with progesterone receptor complementary DNA.
Lin VC; Ng EH; Aw SE; Tan MG; Ng EH; Chan VS; Ho GH
Clin Cancer Res; 1999 Feb; 5(2):395-403. PubMed ID: 10037189
[TBL] [Abstract][Full Text] [Related]
3. The activities of progesterone receptor isoform A and B are differentially modulated by their ligands in a gene-selective manner.
Leo JC; Lin VC
Int J Cancer; 2008 Jan; 122(1):230-43. PubMed ID: 17893877
[TBL] [Abstract][Full Text] [Related]
4. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP.
Sartorius CA; Groshong SD; Miller LA; Powell RL; Tung L; Takimoto GS; Horwitz KB
Cancer Res; 1994 Jul; 54(14):3868-77. PubMed ID: 8033109
[TBL] [Abstract][Full Text] [Related]
5. Progesterone induces focal adhesion in breast cancer cells MDA-MB-231 transfected with progesterone receptor complementary DNA.
Lin VC; Ng EH; Aw SE; Tan MG; Ng EH; Bay BH
Mol Endocrinol; 2000 Mar; 14(3):348-58. PubMed ID: 10707953
[TBL] [Abstract][Full Text] [Related]
6. Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2.
Cui X; Lazard Z; Zhang P; Hopp TA; Lee AV
Oncogene; 2003 Oct; 22(44):6937-41. PubMed ID: 14534541
[TBL] [Abstract][Full Text] [Related]
7. Reduction of human metastatic breast cancer cell aggressiveness on introduction of either form a or B of the progesterone receptor and then treatment with progestins.
Sumida T; Itahana Y; Hamakawa H; Desprez PY
Cancer Res; 2004 Nov; 64(21):7886-92. PubMed ID: 15520195
[TBL] [Abstract][Full Text] [Related]
8. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
9. The antagonists RU486 and ZK98299 stimulate progesterone receptor binding to deoxyribonucleic acid in vitro and in vivo, but have distinct effects on receptor conformation.
Gass EK; Leonhardt SA; Nordeen SK; Edwards DP
Endocrinology; 1998 Apr; 139(4):1905-19. PubMed ID: 9528977
[TBL] [Abstract][Full Text] [Related]
10. Distinct temporal and spatial activities of RU486 on progesterone receptor function in reproductive organs of ovariectomized mice.
Han SJ; Tsai SY; Tsai MJ; O'Malley BW
Endocrinology; 2007 May; 148(5):2471-86. PubMed ID: 17303655
[TBL] [Abstract][Full Text] [Related]
11. Response of human ovarian carcinoma cell lines to antiprogestin mifepristone.
Rose FV; Barnea ER
Oncogene; 1996 Mar; 12(5):999-1003. PubMed ID: 8649817
[TBL] [Abstract][Full Text] [Related]
12. Progesterone induces cellular differentiation in MDA-MB-231 breast cancer cells transfected with progesterone receptor complementary DNA.
Lin VC; Jin R; Tan PH; Aw SE; Woon CT; Bay BH
Am J Pathol; 2003 Jun; 162(6):1781-7. PubMed ID: 12759236
[TBL] [Abstract][Full Text] [Related]
13. [Effects of the antagonist of the classical progesterone receptor on ovulation and maturation of common frog (Rana temporaria L.) oocytes in vitro].
Skoblina MN
Ontogenez; 2002; 33(6):465-70. PubMed ID: 12500556
[TBL] [Abstract][Full Text] [Related]
14. Agonist and antagonist-induced qualitative and quantitative alterations of progesterone receptor from breast cancer cells.
Hurd C; Nag K; Khattree N; Alban P; Dinda S; Moudgil VK
Mol Cell Biochem; 1999 Sep; 199(1-2):49-56. PubMed ID: 10544951
[TBL] [Abstract][Full Text] [Related]
15. Distinct molecular pathways mediate progesterone-induced growth inhibition and focal adhesion.
Lin VC; Woon CT; Aw SE; Guo C
Endocrinology; 2003 Dec; 144(12):5650-7. PubMed ID: 12970168
[TBL] [Abstract][Full Text] [Related]
16. Progesterone prevents radiation-induced apoptosis in breast cancer cells.
Vares G; Ory K; Lectard B; Levalois C; Altmeyer-Morel S; Chevillard S; Lebeau J
Oncogene; 2004 Jun; 23(26):4603-13. PubMed ID: 15064714
[TBL] [Abstract][Full Text] [Related]
17. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
18. Salvicine inactivates beta 1 integrin and inhibits adhesion of MDA-MB-435 cells to fibronectin via reactive oxygen species signaling.
Zhou J; Chen Y; Lang JY; Lu JJ; Ding J
Mol Cancer Res; 2008 Feb; 6(2):194-204. PubMed ID: 18314480
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid and mineralocorticoid cross-talk with progesterone receptor to induce focal adhesion and growth inhibition in breast cancer cells.
Leo JC; Guo C; Woon CT; Aw SE; Lin VC
Endocrinology; 2004 Mar; 145(3):1314-21. PubMed ID: 14617569
[TBL] [Abstract][Full Text] [Related]
20. Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells.
Neubauer H; Adam G; Seeger H; Mueck AO; Solomayer E; Wallwiener D; Cahill MA; Fehm T
Climacteric; 2009 Jun; 12(3):230-9. PubMed ID: 19340614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
